{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:29:53Z","timestamp":1773829793362,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New antifungals, ibrexafungerp and oteseconazole, are now available for treatment of vulvovaginal candidiasis. Both have novel antimicrobial and pharmacokinetic properties and advantages over fluconazole, although comparative trials have involved only placebo. In the absence of allergy, intolerance, and resistance, it is unclear whether these antifungals will replace fluconazole.<\/jats:p>","DOI":"10.1093\/cid\/ciad002","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T01:57:46Z","timestamp":1673143066000},"page":"783-785","source":"Crossref","is-referenced-by-count":24,"title":["New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?"],"prefix":"10.1093","volume":"76","author":[{"given":"Jack D","family":"Sobel","sequence":"first","affiliation":[{"name":"Wayne State University School of Medicine , Detroit, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/cid\/ciy776","article-title":"Estimation of direct healthcare costs of fungal diseases in the United States","volume":"68","author":"Benedict","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/LGT.0b013e318273e8cf","article-title":"Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey","volume":"17","author":"Foxman","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.annepidem.2017.08.010","article-title":"Recurrent vulvovaginal candidiasis","volume":"27","author":"Blostein","year":"2017","journal-title":"Ann Epidemiol"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajog.2015.06.067","article-title":"Recurrent vulvovaginal candidiasis","volume":"214","author":"Sobel","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1120009X.1990.11738981","article-title":"The discovery and profile of fluconazole","volume":"2","author":"Richardson","year":"1990","journal-title":"J Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1067\/mob.2001.115116","article-title":"Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole","volume":"185","author":"Sobel","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"2023030705144240000_","first-page":"5","article-title":"Treatment of vulvovaginal candidiasis: a review of the literature","volume":"24","author":"Dovnik","year":"2015","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"N Engl J Med"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"613.e1","DOI":"10.1016\/j.ajog.2008.06.029","article-title":"Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial)","volume":"199","author":"Donders","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"354","DOI":"10.7326\/0003-4819-123-5-199509010-00006","article-title":"Alopecia associated with fluconazole therapy","volume":"123","author":"Pappas","year":"1995","journal-title":"Ann Intern Med"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/jof4040121","article-title":"An update on the roles of non-albicans Candida species in vulvovaginitis","volume":"4","author":"Makanjuola","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1128\/JCM.42.7.3142-3146.2004","article-title":"Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002","volume":"42","author":"Pfaller","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/LGT.0000000000000496","article-title":"Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans","volume":"24","author":"Collins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1477-7525-11-169","article-title":"Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA","volume":"11","author":"Aball\u00e9a","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/jof8080857","article-title":"Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents","volume":"8","author":"Wiederhold","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","article-title":"Oral ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis","volume":"29","author":"Azie","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e00833\u201317","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jim\u00e9nez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e01961\u201316","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e02611\u201318","DOI":"10.1128\/AAC.02611-18","article-title":"A novel 1,3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis","volume":"63","author":"Larkin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e0056221","DOI":"10.1128\/AAC.00562-21","article-title":"In vitro pH activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida isolates from women with vulvovaginal candidiasis","volume":"65","author":"Sobel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"key":"2023030705144240000_","author":"Goje"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e01304\u201319","DOI":"10.1128\/AAC.01304-19","article-title":"Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","first-page":"e00341\u201316","article-title":"In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","article-title":"A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis","volume":"73","author":"Brand","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100055","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis","volume":"1","author":"Sobel","year":"2022","journal-title":"NEJM Evidence"},{"key":"2023030705144240000_","article-title":"Long-term observation of oteseconazole efficacy against recurrent vulvovaginal candidiasis","volume-title":"Infect Dis Obstet Gynecol","author":"Sobel"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"880.e1","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11908-013-0319-3","article-title":"Genetic basis for recurrent vulvo-vaginal candidiasis","volume":"15","author":"Jaeger","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"2023030705144240000_","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10096-016-2600-5","article-title":"Association of a variable number tandem repeat in the NLRP3 gene in women with susceptibility to RVVC","volume":"35","author":"Jaeger","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad002\/48908712\/ciad002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/5\/783\/49424724\/ciad002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/5\/783\/49424724\/ciad002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T23:14:41Z","timestamp":1679267681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/5\/783\/6970437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,5]]},"published-print":{"date-parts":[[2023,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad002","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,1,5]]}}}